

**WEDNESDAY 16<sup>th</sup> SEPTEMBER 2015 COMMENCING 9.30 AM**  
**AT THE PARK INN HOTEL CARDIFF NORTH, CIRCLE WAY EAST**  
**LLANEDEYRN, CARDIFF, CF23 9XF**

### **AGENDA**

- |                                |              |
|--------------------------------|--------------|
| 1. Welcome and introduction    | Enclosure    |
| 2. Apologies                   |              |
| 3. Declarations of interest    |              |
| 4. Minutes of previous meeting | 1/AWMSG/0915 |

*To protect commercial confidentiality, the first appraisals will be conducted in private.  
The meeting will open to the public at approx 10.30am*

- |   |                            |
|---|----------------------------|
| 5. <b>Appraisal 1 – Full Submission (WPAS)</b><br><b>Riociguat (Adempas<sup>®</sup>)</b> for the treatment of adult patients with WHO functional class II to III with inoperable chronic thromboembolic pulmonary hypertension (CTEPH); or persistent or recurrent CTEPH after surgical treatment to improve exercise capacity  | 2/AWMSG/0915<br>Appendices |
| 6. <b>Appraisal 2 - Full Submission (WPAS)</b><br><b>Riociguat (Adempas<sup>®</sup>)</b> as monotherapy or in combination with endothelin receptor antagonists, for the treatment of adult patients with pulmonary arterial hypertension (PAH) with WHO functional class (FC) II to III to improve exercise capacity. Efficacy has been shown in a PAH population including aetiologies of idiopathic or heritable PAH or PAH associated with connective tissue disease | 3/AWMSG/0915<br>Appendices |

*The meeting will now open to the public*

- |  |                            |
|--|----------------------------|
| 7. <b>Chairman's report (verbal update)</b>  |                            |
| 8. <b>Appraisal 3 - Full Submission</b><br><b>Lisdexamfetamine dimesylate (Elvanse<sup>®</sup> Adult)</b> as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in adults | 4/AWMSG/0915<br>Appendices |

- |     |   |                            |
|-----|---|----------------------------|
| 9.  | AWMSG policy for appraising orphan and ultra-orphan medicines, and medicines developed specifically for rare diseases - feedback from the pilot | 5/AWMSG/0915<br>Appendices |
| 10. | Guidance to Support Safe Use of Long-term Oral Bisphosphonates  | 6/AWMSG/0915               |
| 11. | One System for Health – update  | 7/AWMSG/0915               |
| 12. | Primary Care Prescribing Analysis – Medicines Used in Diabetes  | 8/AWMSG/0915               |
| 13. | Primary Care Antimicrobial Guidelines   | 9/AWMSG/0915               |
| 14. | Guidance on Antimicrobial Prophylaxis Related to Caesarean Section  | 10/AWMSG/0915              |
| 15. | National Prescribing Indicators 2014–2015 Annual Primary Care Prescribing Report  | 11/AWMSG/0915              |

**Date of next meeting:**

**Wednesday 21<sup>st</sup> October in Cardiff**